[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-001", "question": "A 45-year-old male presents with syncope. ECG shows sinus rhythm with first-degree AV block and a right bundle branch block. Echocardiogram reveals a left ventricular ejection fraction (LVEF) of 42% with mild LV dilation. Genetic testing confirms a pathogenic variant in the LMNA gene (Lamin A/C). He has no history of sustained ventricular tachycardia. Which of the following is the most appropriate management?", "options": ["Implantation of a dual-chamber pacemaker", "Implantation of an implantable cardioverter-defibrillator (ICD)", "Implantation of an implantable loop recorder", "Initiation of Amiodarone", "Initiation of Metoprolol and reassessment of LVEF in 3 months"], "answer": "B", "answer_index": 1, "explanation": "Lamin A/C (LMNA) cardiomyopathy carries a disproportionately high risk of malignant ventricular arrhythmias and sudden cardiac death, often independent of the degree of LV dysfunction. Current guidelines recommend ICD implantation for patients with an LMNA mutation and risk factors such as AV block, male sex, or non-missense mutations, even if the LVEF is >35%. A pacemaker alone addresses the conduction disease but leaves the patient unprotected against the high risk of fatal ventricular arrhythmias.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "In patients with **LMNA cardiomyopathy**, even with a mildly reduced LVEF (42%) and conduction system disease (first-degree AV block + RBBB), there is a high risk of malignant ventricular arrhythmias and sudden cardiac death.  \nCurrent guidelines (e.g., AHA/ACC/HRS) recommend ICD implantation for **LMNA mutation carriers** with LVEF ≤ 45% plus significant conduction disease or other risk factors, even without sustained VT or severe systolic dysfunction.  \nA pacemaker alone would not protect against sudden death from ventricular arrhythmias in this high-risk genetic cardiomyopathy.  \n\n**The answer is B**"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-002", "question": "A 68-year-old male presents with a 3-week history of brief, involuntary jerking movements of his right face and arm, occurring up to 40 times per day. He remains conscious during these events. Interictal EEG and brain MRI are unremarkable. He is beginning to show signs of short-term memory impairment. Which of the following is the most appropriate initial treatment?", "options": ["Levetiracetam", "Carbamazepine", "Intravenous Methylprednisolone", "Tissue Plasminogen Activator (tPA)", "Haloperidol"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation is classic for faciobrachial dystonic seizures (FBDS), which are pathognomonic for Anti-LGI1 encephalitis (a form of limbic encephalitis). These seizures are characteristically resistant to standard anti-epileptic drugs but respond dramatically to immunotherapy (steroids, IVIG). Early recognition and treatment with immunotherapy are crucial to prevent the progression to severe cognitive impairment and full-blown limbic encephalitis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient’s presentation — brief, frequent, involuntary jerking movements affecting one side of the face and arm with preserved consciousness — suggests **focal motor seizures** (likely epilepsia partialis continua or frequent focal motor seizures).  \n\nThe normal interictal EEG and brain MRI do not rule out epilepsy, especially since focal seizures can sometimes have a normal EEG.  \n\nThe emerging short-term memory impairment in a 68-year-old with new-onset focal seizures raises concern for a progressive neurological condition such as **autoimmune encephalitis** or a neurodegenerative process, but the most appropriate **initial treatment** for frequent focal motor seizures is an antiepileptic drug.  \n\nAmong the options:  \n- **Levetiracetam** is often used for focal seizures and is well-tolerated in the elderly.  \n- Carbamazepine is also effective for focal seizures but has more drug interactions and side effects in the elderly.  \n- IV methylprednisolone might be considered if an autoimmune encephalitis is confirmed, but not as the *initial* treatment for seizures before further workup.  \n- tPA is for acute ischemic stroke, not indicated here.  \n- Haloperidol is for psychosis, not seizures.  \n\nGiven the need to quickly reduce seizure frequency while further evaluating the cause, **levetiracetam** is a reasonable initial choice.  \n\nThe answer is A"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-003", "question": "A 55-year-old female is admitted to the ICU with sepsis and severe malnutrition. She has a history of chronic back pain managed with acetaminophen. Arterial blood gas shows pH 7.26, pCO2 28 mmHg, HCO3 12 mEq/L. Serum chemistry shows Na 140, Cl 104, BUN 18, Cr 0.8. Lactate is 1.1 mmol/L. Serum ketones are negative. Measured serum osmolality is 295 mOsm/kg (calculated 290). Which of the following is the most likely etiology of her metabolic acidosis?", "options": ["Methanol intoxication", "D-lactic acidosis", "Pyroglutamic acidosis (5-oxoproline accumulation)", "Propylene glycol toxicity", "Salicylate toxicity"], "answer": "C", "answer_index": 2, "explanation": "The patient has a high anion gap metabolic acidosis (AG = 24) with a normal lactate, no ketones, normal renal function, and a normal osmol gap (ruling out toxic alcohols like methanol or propylene glycol). The combination of chronic acetaminophen use, sepsis, and malnutrition leads to glutathione depletion, causing a disruption in the gamma-glutamyl cycle and accumulation of 5-oxoproline (pyroglutamic acid). This is an under-recognized cause of high anion gap acidosis in this specific patient population.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let’s break this down.  \n\n**Step 1 – Identify the acid-base disorder**  \n- pH 7.26 → acidosis  \n- pCO₂ 28 mmHg (low) → respiratory alkalosis or compensation for metabolic acidosis  \n- HCO₃ 12 mEq/L → low → metabolic acidosis  \n- Winter’s formula: expected pCO₂ = 1.5 × HCO₃ + 8 ± 2 = 1.5 × 12 + 8 = 26 ± 2 → pCO₂ 28 fits → pure metabolic acidosis with appropriate respiratory compensation.  \n\n**Step 2 – Calculate anion gap**  \nAG = Na – (Cl + HCO₃) = 140 – (104 + 12) = 24 → high anion gap metabolic acidosis (HAGMA).  \n\n**Step 3 – Check for elevated osmolar gap**  \nCalculated osmolality = 2×Na + glucose/18 + BUN/2.8 + ethanol/4.6 (all in mg/dL)  \nGlucose not given, assume normal ~100 → 100/18 ≈ 5.6  \nBUN 18 mg/dL → 18/2.8 ≈ 6.4  \nEthanol not mentioned, assume 0.  \nSo: 2×140 + 5.6 + 6.4 = 280 + 12 = 292 mOsm/kg (close to 290 given in question).  \nMeasured osmolality = 295 → osmolar gap = 295 – 290 = 5 → normal (<10).  \n\n**Step 4 – Differential for HAGMA**  \nCommon causes: lactic acidosis, ketoacidosis, renal failure, toxins.  \n- Lactate 1.1 → normal → not lactic acidosis.  \n- Ketones negative → not DKA/starvation ketoacidosis.  \n- Normal BUN/Cr → not uremic acidosis.  \n- Osmolar gap normal → not methanol, ethylene glycol, ethanol, or significant propylene glycol.  \n\n**Step 5 – Consider other toxins**  \nSalicylate toxicity → usually causes mixed respiratory alkalosis + metabolic acidosis; here pCO₂ fits pure metabolic compensation, not primary respiratory alkalosis. Also, salicylate often has high osmolar gap if severe? Not always; but in this case, no tinnitus, hyperventilation mentioned, but possible.  \n\nPyroglutamic acidosis (5-oxoproline) → seen in chronic acetaminophen use in malnourished (especially women), sepsis, kidney dysfunction (Cr 0.8 is normal here though). Presents with high AG metabolic acidosis, normal lactate/ketones, normal osmolar gap.  \n\n**Step 6 – Match patient factors**  \n55-year-old female, sepsis, malnutrition, chronic acetaminophen use → classic setting for pyroglutamic acidosis.  \n\n**Step 7 – Eliminate others**  \nA. Methanol → high osmolar gap, not seen here.  \nB. D-lactic acidosis → in short bowel syndrome, not mentioned.  \nC. Pyroglutamic → fits perfectly.  \nD. Propylene glycol → from IV drugs like lorazepam; causes high osmolar gap + high AG metabolic acidosis, but osmolar gap normal here.  \nE. Salicylate → possible, but less specific to chronic acetaminophen + malnutrition; more likely respiratory alkalosis mixed.  \n\nGiven the clues, **C** is most likely.  \n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-004", "question": "A 34-year-old male presents with progressive dyspnea. He has a BMI of 17 kg/m2. Chest radiography shows apical pleural thickening. High-resolution CT demonstrates upper-lobe predominant subpleural fibrosis and a flattened chest configuration ('platythorax'). He has no history of asbestos exposure or connective tissue disease. Which of the following is the most likely diagnosis?", "options": ["Idiopathic Pulmonary Fibrosis (IPF)", "Pleuroparenchymal Fibroelastosis (PPFE)", "Chronic Hypersensitivity Pneumonitis", "Lymphangioleiomyomatosis (LAM)", "Pulmonary Alveolar Proteinosis"], "answer": "B", "answer_index": 1, "explanation": "Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural lung parenchyma, predominantly in the upper lobes. The radiographic hallmark is the 'platythorax' (flattening of the chest cage) due to fibrosis progression. This contrasts with IPF (lower lobe predominant) and Hypersensitivity Pneumonitis (mosaic attenuation, centrilobular nodules).", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient’s presentation includes low BMI, apical pleural thickening on CXR, upper-lobe predominant subpleural fibrosis with platythorax on HRCT, and no typical exposures or connective tissue disease.  \n\nIdiopathic pulmonary fibrosis (IPF) typically has a basilar and subpleural predominance, not apical.  \nChronic hypersensitivity pneumonitis often has mid-zone or diffuse involvement with ground-glass opacities and may have a history of exposure.  \nLymphangioleiomyomatosis (LAM) occurs almost exclusively in women and shows thin-walled cysts throughout the lungs.  \nPulmonary alveolar proteinosis presents with “crazy-paving” pattern, not apical fibrosis and platythorax.  \n\nPleuroparenchymal fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by upper-lobe pleural and subpleural parenchymal fibrosis, often associated with platythorax and low BMI.  \n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-005", "question": "A 24-year-old African American male presents with cyanosis and shortness of breath after taking dapsone for a skin lesion. Pulse oximetry reads 85% and does not improve with supplemental oxygen. Arterial blood gas shows a normal PaO2 but methemoglobin level is 18%. He has a known history of hemolysis after ingesting fava beans. Which of the following is the most appropriate treatment?", "options": ["Methylene Blue 1 mg/kg IV", "Ascorbic Acid (Vitamin C) IV", "Hydroxocobalamin IV", "Hyperbaric Oxygen Therapy", "Sodium Thiosulfate IV"], "answer": "B", "answer_index": 1, "explanation": "The patient has methemoglobinemia precipitated by dapsone. However, his history of hemolysis with fava beans strongly suggests Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Methylene blue is contraindicated in G6PD deficiency because it requires NADPH (generated by G6PD) to reduce methemoglobin; without G6PD, methylene blue is ineffective and can induce severe hemolysis. Ascorbic acid (Vitamin C) or exchange transfusion is the appropriate management.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has dapsone-induced methemoglobinemia with a level of 18% and symptoms.  \nMethylene blue is the first-line treatment for symptomatic methemoglobinemia.  \nHowever, the patient has a history of hemolysis after ingesting fava beans, suggesting possible G6PD deficiency.  \nMethylene blue can cause hemolysis in G6PD-deficient patients, but in severe or symptomatic methemoglobinemia, it is still used with caution; alternative agents (like ascorbic acid) are slower and reserved for mild cases or when methylene blue is contraindicated.  \nGiven the methemoglobin level is 18% and symptomatic, methylene blue remains appropriate unless the patient is known to have severe G6PD deficiency, but the history only mentions hemolysis with fava beans (not proven G6PD deficiency). In clinical practice, methylene blue is still first-line unless strong evidence of severe G6PD deficiency exists, and alternatives are less effective acutely.  \n\nAmong the options:  \n- **A. Methylene Blue** – standard first-line for symptomatic methemoglobinemia.  \n- **B. Ascorbic acid** – slower, used for mild cases or if contraindication to methylene blue.  \n- **C. Hydroxocobalamin** – for cyanide poisoning.  \n- **D. Hyperbaric oxygen** – not primary for methemoglobinemia.  \n- **E. Sodium thiosulfate** – for cyanide poisoning.  \n\nGiven the acute symptomatic presentation, methylene blue is most appropriate.  \n\nThe answer is A"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-006", "question": "A 14-year-old boy with a history of exercise-induced syncope is diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) confirmed by an RyR2 mutation. He is compliant with high-dose Nadolol. A repeat exercise stress test shows a reduction in arrhythmia burden, but he still develops runs of bidirectional ventricular tachycardia at peak exertion. Which of the following is the best next step in management?", "options": ["Switch Nadolol to Metoprolol Succinate", "Add Flecainide", "Perform Radiofrequency Ablation of the ventricular focus", "Implant a dual-chamber pacemaker", "Add Verapamil"], "answer": "B", "answer_index": 1, "explanation": "In patients with CPVT who have breakthrough arrhythmias despite optimal beta-blocker therapy (preferably Nadolol or Propranolol), the addition of Flecainide is the guideline-recommended next step. Flecainide has a direct blocking effect on the cardiac ryanodine receptor (RyR2), addressing the underlying mechanism. Radiofrequency ablation is generally ineffective due to the polymorphic/multifocal nature of the arrhythmia.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has CPVT with a confirmed RyR2 mutation and is on high-dose nadolol (a nonselective beta-blocker), which has reduced but not eliminated exercise-induced ventricular arrhythmias.  \nIn CPVT, if ventricular arrhythmias persist despite maximal tolerated beta-blocker therapy, adding flecainide is a recommended next step, as it targets the RyR2-mediated calcium release and has been shown to reduce arrhythmia burden in combination with beta-blockers.  \n\nSwitching to another beta-blocker (metoprolol) is unlikely to provide additional benefit if already on high-dose nadolol.  \nRadiofrequency ablation is not a standard primary therapy for CPVT.  \nA dual-chamber pacemaker is not indicated here for CPVT.  \nVerapamil is not typically used as add-on therapy in this scenario.  \n\nThe answer is B"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-007", "question": "A 26-year-old female with a history of sensorineural hearing loss and short stature presents with acute onset aphasia and right-sided hemiparesis. MRI shows a T2-hyperintense lesion in the left temporal lobe that does not conform to a vascular territory. Serum lactate is elevated. Which of the following agents is indicated for the acute management of this condition?", "options": ["Intravenous Tissue Plasminogen Activator (tPA)", "Intravenous Arginine", "Intravenous Heparin", "High-dose Aspirin", "Plasma Exchange"], "answer": "B", "answer_index": 1, "explanation": "The clinical picture (stroke-like episode not respecting vascular territories, hearing loss, elevated lactate) is classic for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes). The stroke-like episodes are due to metabolic failure and microvascular angiopathy (nitric oxide deficiency), not thrombotic occlusion. Intravenous Arginine is the recommended acute treatment to improve nitric oxide availability and cerebral blood flow. tPA is not indicated and could be harmful.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient’s history of sensorineural hearing loss and short stature, plus acute stroke-like symptoms with a non‑vascular territory lesion and elevated lactate, points to **MELAS syndrome** (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes).  \n\nIn MELAS, acute stroke-like episodes are treated with **intravenous arginine** (and often continued on oral citrulline/arginine for prevention), as it improves endothelial dysfunction and nitric oxide availability in mitochondrial vasculopathy.  \n\ntPA is contraindicated because this is not an acute thrombotic stroke. Heparin, aspirin, and plasma exchange are not standard acute treatments for MELAS.  \n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-008", "question": "A 32-year-old female is evaluated for palpitations. Labs reveal a TSH of 7.2 mIU/L (High) and Free T4 of 2.9 ng/dL (High). An MRI of the pituitary shows a 5mm hypoenhancing lesion. Sex Hormone Binding Globulin (SHBG) levels are elevated. Which of the following is the most likely diagnosis?", "options": ["Resistance to Thyroid Hormone (RTH) beta", "TSH-secreting pituitary adenoma (TSHoma)", "Graves' disease", "Familial Dysalbuminemic Hyperthyroxinemia", "Heterophile antibody interference"], "answer": "B", "answer_index": 1, "explanation": "Both RTH and TSHoma present with inappropriate TSH secretion (high T4, non-suppressed TSH). The key differentiator is the peripheral tissue response. In TSHoma, peripheral tissues (like the liver) are sensitive to the high thyroid hormone levels, resulting in elevated markers of thyroid action such as Sex Hormone Binding Globulin (SHBG). In RTH, the peripheral tissues are resistant, so SHBG levels are typically normal. The pituitary lesion supports TSHoma, but incidentalomas are common; the metabolic profile (high SHBG) confirms the diagnosis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let’s break this down:  \n\n- **TSH is high** (7.2 mIU/L) → normally, high TSH suggests hypothyroidism, but here **Free T4 is also high** → inappropriate TSH secretion (not suppressed).  \n- MRI shows a **5 mm hypoenhancing pituitary lesion** → possible pituitary adenoma.  \n- **SHBG elevated** → thyroid hormone excess increases SHBG; in true hyperthyroidism, TSH should be suppressed, but here TSH is inappropriately normal/high, so SHBG elevation indicates peripheral tissue effects of high thyroid hormone.  \n- **TSHoma** fits: pituitary tumor secreting TSH → high/normal TSH + high FT4, MRI lesion, elevated SHBG.  \n- **Resistance to Thyroid Hormone (RTH) beta** → also presents with high FT4 and nonsuppressed TSH, but pituitary MRI is usually normal (no adenoma), and SHBG is often normal or low because peripheral tissue is resistant.  \n- **Graves’ disease** → TSH suppressed (not elevated).  \n- **Familial dysalbuminemic hyperthyroxinemia** → artifact in FT4 assay, TSH normal, patient euthyroid, SHBG normal, MRI normal.  \n- **Heterophile antibody interference** → can cause assay artifact, but MRI lesion + SHBG elevation argue for true hormone effects.  \n\nGiven MRI lesion + SHBG elevation + inappropriate TSH with high FT4 → **TSHoma** is most likely.  \n\nThe answer is B"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-009", "question": "A 48-year-old male who works as a tool grinder presents with chronic dry cough and dyspnea. Bronchoalveolar lavage (BAL) reveals multinucleated giant cells that appear to be engulfing other cells ('cannibalistic' giant cells). Which of the following exposures is most likely responsible for this finding?", "options": ["Silica", "Asbestos", "Cobalt", "Beryllium", "Coal dust"], "answer": "C", "answer_index": 2, "explanation": "The presence of 'cannibalistic' multinucleated giant cells in BAL or biopsy is pathognomonic for Hard Metal Lung Disease (Giant Cell Interstitial Pneumonia). This is caused by exposure to Cobalt, often in the form of tungsten carbide alloy used in tool grinding, diamond polishing, or saw sharpening. Beryllium causes granulomas similar to sarcoidosis, not GIP.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient’s occupational history (tool grinder) and BAL findings of “cannibalistic” multinucleated giant cells are classic for **hard metal lung disease** (cobalt-induced giant cell interstitial pneumonia).  \nCobalt exposure, often in the setting of hard metal manufacturing or tool grinding, is the known cause.  \n\nThe answer is C"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-010", "question": "A 52-year-old male presents to the ED 2 hours after ingesting a massive overdose of sustained-release Verapamil. He is hypotensive (BP 60/40 mmHg) and bradycardic (HR 38 bpm). He remains hypotensive despite 3 liters of crystalloid, IV Calcium Gluconate, and IV Glucagon. Which of the following is the most appropriate next therapeutic intervention?", "options": ["High-dose Insulin Euglycemia therapy", "Transvenous Pacing", "Hemodialysis", "IV Amiodarone", "IV Lipid Emulsion (20%)"], "answer": "A", "answer_index": 0, "explanation": "High-dose Insulin Euglycemia (HIE) is the recommended therapy for severe calcium channel blocker toxicity refractory to initial measures (fluids, calcium). Insulin has a positive inotropic effect and improves myocardial glucose utilization in the stressed heart. While lipid emulsion is a salvage therapy, HIE has stronger evidence as a first-line pharmacologic support after calcium/fluids. Transvenous pacing often fails to capture or improve cardiac output in severe CCB poisoning due to global myocardial depression.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has severe hypotension and bradycardia from a massive verapamil overdose that is refractory to initial treatments (fluids, calcium, glucagon).  \nIn calcium channel blocker overdose, high-dose insulin euglycemic therapy (HIET) is a key intervention for cardiogenic shock because it improves myocardial contractility and utilization of carbohydrates.  \nWhile transvenous pacing might address bradycardia, it does not treat the hypotension from decreased contractility, and pacing is often ineffective in this setting.  \nIV lipid emulsion is used for local anesthetic toxicity and some other lipophilic drug overdoses, but it is not first-line for verapamil overdose after HIET.  \nHemodialysis is not effective for verapamil due to high protein binding and large volume of distribution.  \nIV amiodarone would worsen bradycardia and is contraindicated.  \n\nThe most appropriate next intervention is high-dose insulin euglycemia therapy.  \n\nThe answer is (A)"}]